Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.72 |
| ▸ | LIFR | P42702 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | FABP1 | P07148 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422361 | 0.92 | NR1H4 (0.72) | NR1H4LIFR | |
| SCHEMBL4427551 | 0.92 | NR1H4 (0.77) | NR1H4LIFR | |
| SCHEMBL4427502 | 0.91 | NR1H4 (0.71) | NR1H4LIFRMEN1FABP1THRB | |
| SCHEMBL4838926 | 0.91 | NR1H4 (0.70) | NR1H4LIFRMEN1FABP1THRB | |
| SCHEMBL4427382 | 0.90 | NR1H4 (0.69) | NR1H4LIFRMEN1FABP1THRB | |
| SCHEMBL4665679 | 0.85 | NR1H4 (0.77) | NR1H4LIFR | |
| SCHEMBL4840215 | 0.85 | NR1H4 (0.70) | NR1H4LIFRMEN1FABP1THRB | |
| SCHEMBL4422439 | 0.84 | NR1H4 (0.68) | NR1H4LIFRMEN1FABP1THRB | |
| SCHEMBL4830931 | 0.84 | NR1H4 (0.71) | NR1H4LIFRMEN1FABP1THRB | |
| SCHEMBL30080792 | 0.84 | NR1H4 (1.00) | NR1H4LIFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | claimed |
| US-20060258725-A1 | Farnesoid x receptor agonists | SMITHKLINE BEECHAM CORPORATION | 2006-11-16 | — | — | US | claimed |
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | MICROBIA, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319109-B2 | Farnesoid X receptor agonists | SMITH KLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20060258725-A1 | Farnesoid x receptor agonists | SMITHKLINE BEECHAM CORPORATION | 2006-11-16 | — | — | US | disclosed |
| EP-1562915-A1 | FARNESOID X RECEPTOR AGONISTS | SmithKline Beecham Corporation (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004048349-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194494-A1 | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia | CYP46A1, CYP7A1, UGT1A1 | NR1H4 24/4885LIFR 4437/4885MEN1 3433/4885 |
| US-20060258725-A1 | Farnesoid x receptor agonists | NR1H4, GPBAR1, NR1H2 | NR1H4 1/4885LIFR 2155/4885MEN1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.